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Abstract
Objective: Alzheimer disease (AD) is a progressive, degenerative and irreversible neurological disorder with few therapies
available. In search for new potential targets, increasing evidence suggests a role for the endocannabinoid system (ECS) in
the regulation of neurodegenerative processes.
Methods: We have studied the gene expression status and the epigenetic regulation of ECS components in peripheral
blood mononuclear cells (PBMCs) of subjects with late-onset AD (LOAD) and age-matched controls (CT).
Results: We found an increase in fatty acid amide hydrolase (faah) gene expression in LOAD subjects (2.3060.48) when
compared to CT (1.0060.14; *p,0.05) and no changes in the mRNA levels of any other gene of ECS elements. Consistently,
we also observed in LOAD subjects an increase in FAAH protein levels (CT: 0.7560.04; LOAD: 1.1160.15; *p,0.05) and
activity (pmol/min per mg protein CT: 103.8068.73; LOAD: 125.1064.00; *p,0.05), as well as a reduction in DNA
methylation at faah gene promoter (CT: 55.9064.60%; LOAD: 41.2064.90%; *p,0.05).
Conclusions: Present findings suggest the involvement of FAAH in the pathogenesis of AD, highlighting the importance of
epigenetic mechanisms in enzyme regulation; they also point to FAAH as a new potential biomarker for AD in easily
accessible peripheral cells.
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Introduction
Alzheimer disease (AD) is the most frequent form of dementia in
the elderly, affecting more than 25 million people worldwide; it is
characterized by progressive deterioration of cognition and
memory as a result of selective neuronal loss in the hippocampus
and cerebral cortex.
Current treatments for AD provide only palliative approaches
[1], and in the search for new therapeutic targets the ‘‘endocan-
nabinoid system’’ (ECS) recently emerged as a promising candi-
date, due to its role in neuroinflammatory and neurodegenerative
diseases [2,3]. In the past centuries, cannabinoids have been used
for the treatment of various diseases [4], but only recently the
mechanisms by which these compounds exert their effects began
to be understood. G-protein-coupled type-1 and type-2 cannabi-
noid receptors (CB1 and CB2), located in both the central nervous
system and the periphery, have been characterized along with
their two main endogenous ligands, the ethanolamine of
arachidonic acid [‘‘anandamide’’ (AEA)], and 2-arachidonoyl-
glycerol (2-AG) [4,5]. AEA and 2-AG are endocannabinoids
(eCBs) able to activate also non-CB1/non-CB2 receptors and/or
a purported ‘‘CB3’’ (or GPR55) receptor. Furthermore AEA, but
not 2-AG, behaves as a ligand to type-1 vanilloid receptor
(TRPV1) channels (for a detailed review see Pertwee [6]). AEA is
synthesized through multiple pathways, of which the best
characterized is catalyzed by N-acyl-phosphatidylethanolamines-
hydrolyzing phospholipase D (NAPE-PLD). The biological activity
of AEA through its receptors is terminated upon intracellular
degradation by fatty acid amide hydrolase (FAAH). Instead, 2-AG
is mainly synthesized by an sn-1-specific diacylglycerol lipase
(DAGL), and is degraded by a specific monoacylglycerol lipase
(MAGL) (for detailed review see Di Marzo [7]). AEA, 2-AG and
congeners, their target receptors and the respective metabolic
enzymes form the ECS [5,8,9,10].
Accumulated evidence shows that both exogenous plant-derived
and endogenous cannabinoids are neuroprotective [11]. Addition-
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ally, the ECS is known to play a key role in pathological events
occurring in the AD brain: excitotoxicity [12], oxidative stress [13]
and inflammation [2]. Yet, few studies investigated alterations of
the ECS in normal or pathological aging (reviewed in Paradisi et
al. [14]). For example, it has been reported that CB1 receptors are
decreased in aged rats [15,16] and in human pathological
conditions affecting basal ganglia structures [17], and CB1
receptor in human AD brains mainly demonstrates no changes
[18,19,20] or decreased levels [21,22].
CB2 is overexpressed on microglia within the senile plaque, and
so is FAAH that in turn contributes to the inflammatory process of
AD and to the release of pro-inflammatory molecules, such as
arachidonic acid, from AEA and related eCBs [11]. Consistently
with these results, an increase of both CB2 and FAAH expression
was found in glial cells surrounding Ab plaques in tissue samples
from subjects with Down syndrome [23], a condition that shares
common pathways with AD [24].
Moreover, in peripheral whole blood from AD subjects, an
increase in CB2 gene expression was observed in patients with
lower Mini Mental Status Exam (MMSE) scores [25]. In another
study using peripheral markers, there were no differences in eCB
concentrations in plasma samples from patients with AD and
healthy controls. Moreover, circulating eCBs were not correlated
with cognitive performance in subjects at risk of AD [26]. Overall,
ECS gene expression and eCBs signaling in AD remain largely
unexplored [27].
Our first aim was thus to evaluate possible changes of ECS gene
transcription occurring in Late Onset (after age 65) AD (LOAD)
subjects. We conducted the study on peripheral blood mono-
nuclear cells (PBMCs), that are accessible cells with potential for
biomarker discovery in neuroinflammatory disorders [2]. In this
context, the study of gene regulation in blood cells from living
patients offers the possibility to go through the whole history of the
disorder (including response to pharmacological, metabolic and
environmental events) in a more comprehensive perspective,
compared to the single point postmortem brain studies.
Gene expression in the nervous system is modulated by
epigenetic processes which consist of mitotically heritable, but
reversible, changes in gene accessibility that occur without
a change in the genomic DNA sequence [28,29]. Main epigenetic
mechanisms essentially include DNA methylation and histone
modifications [30]. DNA methylation, in particular, consists of the
transfer of a methyl group to position 5 of the cytosine pyrimidine
ring of a cytosine guanine dinucleotide (CpG), which ultimately
blocks the binding of transcription factors causing chromatin
compaction and gene silencing [28].
Since epigenetic mechanisms have been also associated with
a range of neurobiological processes in the brain, including central
nervous system development, learning, memory and neurodegen-
eration [28], we investigated the role of DNA methylation in the
regulation of ECS gene transcription in LOAD.
It is important to notice that PBMCs may be also a useful model
of epigenetic gene regulation in the brain [31]. In fact, it has been
shown that PBMCs share much of the non-synaptic biochemical
environment of neurons and contain the full complement of
epigenetic enzymes found in most tissues, including neurons and
peripheral nucleated cells [32,33].
Methods
Ethics statement
The study has been approved by the Institutional Review board
of the Department of Internal Medicine, University of Milan,
Fondazione Ca` Granda, IRCCS Ospedale Maggiore Policlinico,
Mangiagalli e Regina Elena. Informed written consent to
participate in this study was given by patients and their caregivers.
Subjects
The study involved LOAD patients (mean age 6 standard
deviation: 79.4766.30 years – 23/9 females/males; n = 33 for
DNA methylation studies and protein level detection, n = 13 for
gene expression analysis) and non-demented age- and sex-matched
healthy CT with similar educational levels (mean age 6 standard
deviation: 79.9866.36 years; n = 33 for DNA methylation studies
and protein level detection, n = 12 for gene expression analysis).
All subjects were Caucasians living in Northern Italy, who were
prospectively enrolled from a larger population of outpatients
attending the Geriatric Unit of the Ospedale Maggiore IRCCS,
University of Milan, Italy.
LOAD patients fulfilled the NINCDS-ADRDA criteria [34]. A
computed tomography or magnetic resonance imaging scan
corroborated the diagnosis of AD. Controls were carefully assessed
in order to exclude the presence of neurological and cognitive
disorders of any kind. Blood from all patients and controls was
collected at the same time in the morning. At the recruitment,
none of the subjects showed clinical signs of inflammation and
were treated with acetylcholine esterase inhibitors.
All subjects and their relatives gave informed consent, and the
study protocol was approved by the university hospital’s Ethics
Committee. The ApoE genotypes were determined as previously
described [35].
All subjects underwent functional and cognitive evaluations.
Basic activities of daily living (ADL; possible score: 0–6, with 6
being the best score) and instrumental ADLs (IADL; possible
score: 0–8, with 8 being the best score) were assessed, as well as
cognitive measures obtained using the Mini Mental Status Exam
(MMSE) [36,25], a widely used dementia severity test with scores
Table 1. Description of study sample.
Test CT LOAD p values (Mann-Whitney U test)
MMSE 28.3760.22 17.6561.39 ,0.0001
ADL 5.1560.23 3.6360.29 0.0006
ApoE genotype CT LOAD p value (X2 test)
e4 carriers (%) 17 43 0.032
e4 non carriers (%) 83 57
Data are represented as means 6 SEM. Mini-Mental-State Examination (MMSE) normal range: 0–30. Activities of Daily Living (ADL) normal range: 0–6.
doi:10.1371/journal.pone.0039186.t001
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ranging from 0 to 30 points. Table 1 summarizes the detailed
pathological informations about CT and LOAD subjects.
Analysis of gene expression by quantitative real-time
reverse transcription–polymerase chain reaction (qRT-
PCR)
PBMCs were separated by density gradient using the Lympho-
lyte-H kit (Cedarlane Laboratories Limited, Canada), and total
RNA was isolated using standard procedures [37]. Relative
abundance of each mRNA species was assessed by real-time
qRT-PCR, using iQ SYBR Green Supermix (Bio-Rad, Hercules,
CA, USA) on an DNA Engine Opticon 2 Continuous Fluores-
cence Detection System (MJ Research, Waltham, MA, USA). All
data were normalized to the endogenous reference gene glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH). Differences in
threshold cycle (Ct) number were used to quantify the relative
amount of PCR target contained in each tube. Relative expression
of different gene transcripts was calculated by the Delta-Delta Ct
(DDCt) method and converted to relative expression ratio
(22DDCt) for statistical analysis. After PCR, a dissociation melting
curve was constructed in the range of 60uC to 95uC to evaluate the
specificity of the amplification products. The primers used for
PCR amplification, designed using Primer 3, are shown in table 2.
Analysis of DNA methylation by methylation-specific
primer real-time PCR
Genomic DNA was extracted from blood using a salting-out
method [38], and was subjected to bisulphite modification using
a commercially available modification Kit (Zymo Research,
Irvine, CA, USA). Methylation analysis was performed by
fluorescence-based real-time PCR. Amplified faah sequence
contained 18 CpG sites (M_FAAH), and was located within exon
1 of the gene. It has recently been shown that DNA methylation
downstream of the transcription start site, in the region of the first
exon, is much more tightly linked to transcriptional silencing than
is methylation in the upstream promoter region [39]. PCR was
also performed for non-CpG-containing region of myoD, that
served as control gene. Bisulfite-modified CpGenomeTM universal
unmethylated DNA (Chemicon International, Temecula CA,
USA) was used as negative control. The percentage of methylation
was calculated by the 22DDCt method, where DDCt = (Ct,
M_FAAH – Ct, myoD) sample – (Ct, M_FAAH – Ct, myoD)
fully methylated DNA, multiplying by 100. For relative quantifica-
tions, standard curves were generated separately for each gene and
myoD from serial dilutions of bisulfite modified CpGenomeTM
universal methylated DNA (Chemicon International, Temecula
CA, USA). To confirm our results, we also used primers for the
unmethylated DNA sequence (U_FAAH) in selected DNA bi-
sulfite-converted samples calculating the % of methylation as
Table 2. Primers used for gene expression and DNA methylation analysis.
Human Gene Forward Reverse
CB1 CCTTTTGCTGCCTAAATCCAC CCACTGCTCAAACATCTGAC
CB2 TCAACCCTGTCATCTATGCTC AGTCAGTCCCAACACTCATC
‘‘CB3’’ ATCTACATGATCAACCTGGC ATGAAGCAGATGGTGAAGACGC
TRPV1 TCACCTACATCCTCCTGCTC AAGTTCTTCCAGTGTCTGCC
NAPE-PLD TTGTGAATCCGTGGCCAACATGG TACTGCGATGGTGAAGCACG
FAAH CCCAATGGCTTAAAGGACTG ATGAACCGCAGACACAAC
DAGL GCCACCAAGAGGAGGCAGCG CCGCGTGCAGCAGAGGAACA
MAGL ATGCAGAAAGACTACCCTGGGC TTATTCCGAGAGAGCACGC
GAPDH GATTCCACCCATGGCAAATTC TGGGATTTCCATTGATGACAAG
M_FAAH CGTTTTGGTTTGTTGTTTCGT CTATCCATATTCTCCAAACCCG
U_FAAH GTTGTTTTGGTTTGTTGTTTTGT CTATCCATATTCTCCAAACCCACT
myoD CCAACTCCAAATCCCCTCTCTAT TGATTAATTTAGATTGGGTTTAGAGAAGGA
doi:10.1371/journal.pone.0039186.t002
Figure 1. ECS gene expression levels. ECS genes (panel a:
receptors; panel b: metabolic enzymes) expression in PBMCs from
LOAD subjects. Bars represent 22DDCt values calculated by Delta–Delta
Ct (DDCt) method. Expression was normalized to GAPDH, and data are
represented as means 6 SEM. *p,0.05 vs control.
doi:10.1371/journal.pone.0039186.g001
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previously reported [40–41]. These latter data are not shown to
avoid redundancy. The primers are shown in table 2.
Analysis of protein levels by Western blotting
PBMCs were disrupted by lysis buffer containing 2% SDS and
0.1% protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO,
USA). Equal amounts of total extracts (30 mg of protein) were
electrophoresed on 10% acrylamide gels and transferred to PVDF
membranes (Amersham Biosciences, Psicataway, NJ, USA).
Membranes were saturated with a solution of 5% non-fat dry
milk, then they were probed with goat anti-FAAH polyclonal
antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA)
at 1:250 dilution. Secondary antibody against goat IgG (Santa
Cruz Biotechnology Inc.) was used at 1:1000. The antigen-
antibody complex was detected by enhanced chemiluminescence
reagents (ECL, Amersham Biosciences), quantifying the intensities
of the immunoreactive bands by densitometric analysis through
the ImageJ software (NIH, Bethesda, Maryland, USA). The
specificity of the anti-FAAH antibody was checked by using mouse
liver extracts as positive control [42], and human HeLa cell lysates
as negative control [43], under the same experimental conditions.
Equal loading was further ascertained by re-probing membranes
with a mouse anti-b-actin monoclonal antibody, diluted 1:10000
(Cell Signaling, Billerica, MA, USA).
Assay of FAAH activity
The hydrolysis of 2.5 mM 3H-AEA (200 Ci/mmol, from Perkin
Elmer, MA, USA) by FAAH (E.C. 3.5.1.4) was assayed in PBMC
extracts (20 mg protein per test) by reversed-phase high perfor-
mance liquid chromatography, as reported [44]. FAAH activity
was expressed as pmol 3H-arachidonic acid released from 3H-AEA
per min per mg protein.
Statistical analysis
All results are expressed as mean 6 standard error of the mean
(SEM). Statistical differences of faah gene expression, DNA
methylation changes at faah promoter as well as FAAH protein
levels and enzyme activity of LOAD patients versus control subjects
were calculated by the non-parametric Mann-Whitney U test
through the Prism 5 program (GraphPad Software Inc., San
Diego, CA). The evaluation of DNA methylation changes at faah
promoter in relation to MMSE scores was analyzed by one-way
ANOVA, followed by Newman-Keuls Multiple Comparison Test.
To examine if a correlation existed between DNA methylation and
MMSE score or gene expression changes, non-parametric
Spearman or Pearson correlation analysis was performed. p
values,0.05 were considered statistically significant.
Results
Gene expression of all major ECS elements in LOAD subjects
and healthy controls was quantified and only FAAH mRNA was
found to be altered by the disease (Figure 1). A significant increase
of faah gene expression was observed in LOAD subjects compared
to controls (LOAD: 2.3060.48; CT: 1.0060.14;* p,0.05)
(Figure 2a). Also a decreased DNA methylation at faah gene was
observed in LOAD patients compared to controls (CT:
55.9064.60%, LOAD: 41.2064.90%; * p,0.05) (Figure 2b).
Consistently, a significant inverse correlation between gene
expression and DNA methylation levels (Spearman r =20.5326,
Figure 2. Genetic and epigenetic regulation of faah gene. a:
Levels of FAAH mRNA in PBMCs from LOAD patients (n = 13) and
controls (n = 12); b: Amount of methylated DNA at faah gene in controls
(n = 33 ) and LOAD subjects (n = 33); c: Correlation between faah gene
expression and % change of DNA methylation in LOAD subjects. Data
were compared by Spearman’s rank correlation coefficient (p,0.05,
r =20.5326). Scatter dots represent 22DDCt values calculated by Delta-
Delta Ct (DDCt) method, as described in the Materials and Methods
section.
doi:10.1371/journal.pone.0039186.g002
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* p,0.05) was evident in all samples that were large enough to
allow both assays (Figure 2c).
When data were stratified according to functional and cognitive
tests, a significantly lower level of DNA methylation at faah gene
was observed in LOAD subjects with lower levels of MMSE, and
severe AD (score range 0–10 (n = 7): 1963%; * p,0.05 Newman-
Keuls) compared to the rest of the samples, moderate AD (score
range 11–20 (n = 8): 59611%) and incipient AD and/or controls
(score range 21–30 (n = 24): 5066%) (ANOVA: p = 0.0396;
F = 3.545) (Figure 3a). Moreover, within subjects with moderate
and severe AD, it was also observed a significant correlation with
DNA methylation levels (Pearson r = 0.6240, *p,0.05) (Figure 3b).
Protein samples from 28/32 CT/LOAD subjects were
randomly pooled in five groups for FAAH protein detection.
Western blot analysis revealed an increase in the levels of FAAH
protein in LOAD subject compared to controls (1.1160.15;
0.7560.04; *p,0.05, n = 5) (Figure 4a). A significant difference
was also evident when comparing FAAH activity between CT
(103.8068.73 pmol/min per mg protein) and LOAD
(125.1064.00 pmol/min per mg protein; *p,0.05) (Figure 4b).
Discussion
Many studies have recently documented a role for ECS in
several neurological diseases, among which AD is a new promising
area of research [27,45].
Inflammatory processes are closely associated to the neuropath-
ological and cognitive syndromes of AD [46], and the anti-
inflammatory actions of ECS may allow their exploitation for the
treatment of the disease [47].
Here, we investigated possible changes in gene expression of all
major ECS elements in PBMCs of LOAD subjects compared to
healthy controls, and we observed a remarkable up-regulation of
the faah gene in AD subjects without changes in any other ECS
gene (Figure 1). FAAH is one of the enzymes involved in the
termination of endocannabinoid signaling, and it is able to
hydrolyze AEA and other fatty acid amides. FAAH protein is
abundantly expressed in large neurons [48], as well as in white
matter astrocytes [49]. In vivo and in vitro data indicate that FAAH
inhibition could be a promising therapeutic strategy against
excitotoxic damage.
We thus confirmed in human peripheral cells the faah mRNA
up-regulation already observed in AD postmortem brains [18].
Unfortunately, due to methodological constraints, it was not
possible to isolate PBMC for RNA extraction from all patients
recruited. Others have mainly focused the attention on the mRNA
expression of CB1 receptors, the most abundant G-protein-
coupled receptor within the brain, although with conflicting
results [19,21,22]. To the best of our knowledge this is the first
study on the expression of all the elements of the ECS in PBMCs
of LOAD subjects, where faah gene clearly appears to be the only
component of the system that is altered in the disease.
These intriguing results prompted us to investigate in more
detail the regulation of FAAH expression in AD. Our aim was not
only to evaluate changes in mRNA, protein and activity levels, but
also to study the epigenetic regulation of faah gene transcription.
Indeed we report that FAAH protein, and hence enzyme
activity, increased in PBMCs of LOAD subjects (Figure 4a–b).
Again, this finding in peripheral cells is in agreement with previous
results in postmortem AD brains [18], where FAAH protein up-
regulation within plaques was suggested to lead to an increase in
metabolites from AEA degradation (such as arachidonic acid).
Such metabolites could contribute to the inflammatory process
occurring in AD. This hypothesis is also in line with the
neuroprotective effect observed upon CB1 receptor stimulation
[12], and with the role that ECS might have in pathological
processes like amyloid protein accumulation in AD [3]. In this
context, it should be noted that it has been recently reported that
circulating eCBs levels do not correlate with cognitive perfor-
mance in subjects at risk of AD [26]. However, the endogenous
tone of AEA is controlled by multiple biosynthetic and hydrolytic
pathways [7], therefore it is not unprecedented that a difference in
FAAH activity and expression is not reflected by a different
content of AEA. Moreover, blood cells other than PBMCs are
known to actively metabolize AEA, e.g. platelets [50], thus FAAH
Figure 3. faah DNA methylation levels vsMMSE score. a: Amount of methylated DNA at faah gene in LOAD subjects subgrouped on the basis
of MMSE score; b: Correlation between changes in DNA methylation at faah gene and LOAD subjects with severe AD, based on MMSE score. Data
were compared by Pearson’s rank correlation coefficient (p,0.05, r =20.6240).
doi:10.1371/journal.pone.0039186.g003
Fatty Acid Amide Hydrolase and AD
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39186
of PBMCs is only one of the contributors to the control of
circulating AEA concentrations. At any rate, our data clearly
identify FAAH from PBMCs as a potential biomarker of AD.
Interestingly, our present findings speak in favor of the
relevance of PBMCs as peripheral markers that could mirror the
pathology within the brain. In most of the illnesses, it is possible to
study the affected tissue while the patient is still alive, yet this
option is rather difficult in subjects with neurodegenerative
disorders. Previous studies already suggested that PBMCs are
a more accessible source of biomarkers in psychiatric [31] and
neurodegenerative/neuroinflammatory disorders [2]. We thus
studied DNA methylation at faah gene in PBMCs, since epigenetic
mechanisms represent a link between gene expression alterations
and environmental factors. In line with this, we and others have
suggested a potential role for epigenetic effects in the development
of AD. For instance, recent data from our group showed
a significant increase in Pin1 gene expression together with
a significant decrease in gene promoter methylation in PBMCs of
LOAD patients [51]. It has also been observed that AD patients
display high homocysteine and low B12 vitamin and folate in
blood, suggesting a dysregulation in the S-adenosylmethionine
cycle that contributes methyl donors for DNA methylation [52].
Moreover, an unusual methylation pattern occurring with age in
LOAD subjects has been identified [53]. Here, we found
a correlation between the increase of FAAH mRNA and the
reduction of DNA methylation in LOAD subjects. Moreover, in
those patients with the most severe cognitive impairment we
observed the lowest levels of the epigenetic mark.
Again, this is the first report showing a link between selective
faah gene expression alteration and DNA methylation in LOAD.
The reversibility of epigenetic marks might be of particular clinical
importance to elucidate the action of existing pharmacological
treatments, as well as to develop new therapeutic tools.
Epidemiologic and laboratory studies suggest the use of non-
steroidal anti-inflammatory drug (NSAIDs), which act as non-
selective inhibitors of cyclooxygenases (COXs), for the treatment
of AD, based on their effect in reducing the inflammation
surrounding amyloid plaques [54]. AEA is also a substrate of
COX-2, and it has been suggested that its oxygenation serves as
a mechanism to terminate eCBs signaling [55]. This is of
particular interest in the central nervous system, where COX-2
inhibitors might achieve therapeutic effects in AD by increasing
eCBs levels. However, due to the well-known side effects of
NSAIDs, our data could give a more realistic alternative for AD
treatment. In fact, it is well-known that AEA protects brain from
inflammation and, based on our observations, we could speculate
that inhibitors of FAAH activity could be more beneficial than
NSAIDs in preventing the inflammatory process associated with
Ab deposition.
In conclusion, this study adds new information on ECS
alterations in normal or pathological aging and, on the basis of
the relationship between the brain and the periphery in AD, it also
suggests a possible role for FAAH not only as a peripheral
biomarker but also as new possible therapeutic target for AD.
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